Bladder cancer: Molecular determinants of personalized therapy

Antonio Lopez-Beltran, Matteo Santoni, Francesco Massari, Chiara Ciccarese, Giampaolo Tortora, Liang Cheng, Holger Moch, Marina Scarpelli, Carlos Reymundo, Rodolfo Montironi

12 Scopus citations

Abstract

Several molecular and genetic studies have provided new perspectives on the histologic classification of bladder tumors. Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer. All these changes are behind the use of non-traditional approach to therapy of bladder cancer patients and are ready to change our daily practice of uro-oncology. The observed correlation of some molecular alterations with tumor behavior and the identification of their targets at cellular level might support the use of molecular changes together with morphological data to develop new clinical and biological strategies to manage patients with urothelial cancer. The current review provides comprehensive data to support personalized therapy for bladder cancer based on an integrated approach including pathologic and clinical features and molecular biology.

Original languageEnglish (US)
Pages (from-to)115-124
Number of pages10
JournalCurrent Drug Targets
Volume16
Issue number2
DOIs
StatePublished - Jan 1 2015

    Fingerprint

Keywords

  • Bladder cancer
  • Genito-urinary cancers
  • Molecular pathology
  • Personalized therapy
  • Precision oncology
  • Targeted therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Lopez-Beltran, A., Santoni, M., Massari, F., Ciccarese, C., Tortora, G., Cheng, L., Moch, H., Scarpelli, M., Reymundo, C., & Montironi, R. (2015). Bladder cancer: Molecular determinants of personalized therapy. Current Drug Targets, 16(2), 115-124. https://doi.org/10.2174/1389450116666150204115756